UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~ Washington, D.C. 20549

~~FORM~~ Form 8-K

~~CURRENT~~ Current ~~REPORT~~Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~Securities~~ Date ~~Exchange~~of ~~Act~~Report (Date of ~~1934~~earliest event reported): 03/05/2009

Date of Report (Date of earliest event reported): March 3, 2009

CV THERAPEUTICS, INC.

(Exact name of ~~Registrant~~registrant as specified in its charter)

Delaware		0-21643		43-1570294
(State or other jurisdiction of incorporation)		(Commission File No.)		(I.R.S. Employer Identification No.)

Commission File Number: 0-21643

3172 Porter Drive, Palo Alto, California		94304
Delaware		43-1570294
(Address of principal executive offices)		(Zip Code)
(State or other jurisdiction of		(IRS Employer
incorporation)		Identification No.)

~~Registrant’s~~ 3172 ~~telephone~~Porter ~~number~~Drive, ~~including~~Palo ~~area~~Alto, ~~code:~~CA ~~(650) 384-8500~~ 94304

(Address of principal executive offices, including zip code)

650-384-8500

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

¨ Item ~~Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240~~8.~~14a-12)~~01. Other Events

¨ On ~~Pre-commencement~~March ~~communications~~5, ~~pursuant~~2009, toCV ~~Rule~~Therapeutics, ~~14d~~Inc. announced that CVT-23619, a novel oral compound for potential treatment of cardiometabolic diseases, was well tolerated with no serious adverse events and was associated with a reduction of free fatty acids (bFFA). ~~under~~This Phase 1, single-blind, placebo-controlled, single ascending dose study evaluated the ~~Exchange~~safety, ~~Act~~tolerability ~~(17~~and ~~CFR~~pharmacokinetics ~~240.14d~~of oral CVT-~~2(b))~~3619, a partial A1 adenosine receptor agonist, in 55 healthy and 23 obese volunteers. No clinically meaningful changes in heart rate or blood pressure were observed in the study.

The foregoing description is qualified in its entirety by reference to the press release dated March 5, 2009, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01. OTHER EVENTS

On March 3, 2009, CV Therapeutics, Inc. announced the commercialization of Ranexa® (ranolazine prolonged-release tablets) to physicians in the United Kingdom and Germany.

The foregoing description is qualified in its entirety by reference to the press release dated March 3, 2009, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

* * * * *

~~ITEM~~ Item 9.01. Financial ~~FINANCIAL~~Statements ~~STATEMENTS~~and ~~AND EXHIBITS~~Exhibits

(d) Exhibits.

99.1 Press Release dated March 5, 2009.

~~99.1~~ Signature(s) ~~Press Release dated March 3, 2009.~~

~~SIGNATURES~~ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		CV THERAPEUTICS, INC.


Date: March 05, 2009	By:	/s/ TRICIA BORGA SUVARI
		TRICIA BORGA SUVARI
		Senior Vice President and General Counsel

Date: March 3, 2009	CV THERAPEUTICS, INC.
	By:	/s/ Tricia Borga Suvari
		Tricia Borga Suvari
		Senior Vice President and General Counsel

Exhibit Index

EXHIBIT INDEX

Exhibit No.		Description
EX-99.1		Press Release dated March 5, 2009.

Exhibit No.		Description
EX-99.1		Press Release dated March 3, 2009.

Filing Compare · CV THERAPEUTICS INC